title: Well-being of obese individuals: therapeutic perspectives.
abstract: The history of pharmacologic treatment of obesity is characterized by too much focus on efficacy and too little on safety, which has led to withdrawals of drugs from the market after serious adverse events. The development of new drug targets for the management of obesity will definitively need to address effects of the CNS and overall cardiovascular safety in the early stages in order to avoid the mistakes from the past. For instance, weight loss can increase the symptoms of depression and promote a state of psychobiological vulnerability favoring weight regain. Body-weight management should then seek a balance between the health benefits of weight loss and its potential risks, a 'zone' that is associated with an optimal psychobiological well-being.
authors.affiliation: Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg C, Denmark. jepc@life.ku.dk
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Chaput
authors.forename: Angelo
authors.initials: A
authors.lastname: Tremblay
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000639:trends; D003863:Depression / Q000150:complications / Q000188:drug therapy; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000188:drug therapy*; D010549:Personal Satisfaction; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D014150:Antipsychotic Agents